Reuters broke the news that Merck, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics. Springworks’ shares jumped nearly 49% on the Reuters story to touch its highest level since April 2022. Merck later released a statement confirming the Reuters scoop.
The post Germany’s Merck in advanced talks to acquire US biotech firm Springworks appeared first on Reuters Best.
Leave a Reply